BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon Inc. today announced the publication of data from studies of Plexxikon’s targeted cancer compound published in The Proceedings of the National Academy of Sciences by a team of scientists from Plexxikon and the Wistar Institute. Plexxikon’s novel anti-cancer compound selectively destroys tumor cells which contain the B-RafV600E cancer-causing mutation, a defect present in most melanomas and thyroid tumors and a large number of colorectal and other cancers. Patients with the BRAFV600E gene may have particularly aggressive tumors often resulting in much poorer survival outcomes.
